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OBJECTIVES To investigate the influence of blood glucose on platelet-dependent thrombosis (PDT).
BACKGROUND Elevated blood glucose is a predictor of adverse cardiovascular risk independent of a diagnosis
of diabetes, possibly due to adverse effects promoting thrombosis. The effects of blood glucose
on PDT have not been characterized.
METHODS An ex vivo extracorporeal perfusion protocol was used to measure PDT in 42 patients with
stable coronary artery disease (CAD). The Badimon chamber was perfused with unantico-
agulated venous blood and PDT evaluated using computerized morphometry. Whole blood
impedance aggregometry and flow cytometry evaluated platelet aggregation and P-selectin
expression, respectively.
RESULTS Using a multivariate stepwise regression model, blood glucose was the best independent
predictor of PDT (R2 5 0.19, p , 0.008), followed by apolipoprotein B (R2 5 0.18, p 5
0.002) and intracellular magnesium levels (R2 5 0.12, p 5 0.02). Platelet-dependent
thrombosis was significantly greater in patients with blood glucose ., compared with #, the
median value of 4.9 mmol/l (159 6 141 vs. 67 6 69 mm2/mm, p , 0.01). Neither platelet
aggregation nor P-selectin expression was significantly different between the two groups.
Insulin levels correlated with blood glucose (r 5 0.56, p 5 0.0003), but were not
independently associated with either PDT, platelet aggregation or P-selectin expression. A
two-way analysis of variance demonstrated an interaction between insulin (.126 pmol/l) and
blood glucose (.4.9 mmol/l) in modulating PDT (F [1,38] 5 8.5, p , 0.006).
CONCLUSIONS Blood glucose is an independent predictor of PDT in stable CAD patients. The relationship
is evident even in the range of blood glucose levels considered normal, indicating that the risk
associated with blood glucose may be continuous and graded. These findings suggest that the
increased CAD risk associated with elevated blood glucose may be, in part, related to
enhanced platelet-mediated thrombogenesis. (J Am Coll Cardiol 2000;35:300–7) © 2000 by
the American College of Cardiology
Diabetes mellitus is associated with increased incidence of
cardiovascular events (1–3), with atherosclerotic coronary
artery disease (CAD) accounting for most of the associated
morbidity and mortality (4). The enhanced CAD risk in
diabetes appears to be related to elevated blood glucose
levels (5) or increased plasma insulin levels (6). Recent
epidemiologic evidence suggests that, similar to CAD risk
associated with increasing cholesterol concentrations or
systolic blood pressure, risk associated with blood glucose
may also be continuous and graded, with increased risk
evident even in the normal “nondiabetic” range (5).
Biological mechanisms to explain the enhanced CAD
risk in diabetes are less well explored. In particular, the
hypothesis that diabetes may increase CAD risk due to an
enhanced tendency to intravascular thrombosis is untested
(7–9). Because platelets play a key role in acute vascular
thrombosis, the increased risk of cardiovascular events
among diabetic patients may be, in part, due to altered
platelet function. Evidence for increased platelet adhesion
and aggregation (10–12), platelet-dependent thrombin
generation (13,14) and impaired platelet-mediated vasodi-
lation (15) has been demonstrated in diabetics. Alteration of
platelet function in diabetes appears to be mediated by
elevated blood glucose (16).
From the *Preventive and Rehabilitative Cardiac Center and the †Atherosclerosis
Research Center, Cedars-Sinai Burns and Allen Research Institute, Division of
Cardiology, Department of Medicine, Cedars-Sinai Medical Center and the ‡UCLA
School of Medicine, Los Angeles, California. This study was supported by Save A
Heart Foundation, Los Angeles, California, Blaine Company, Inc., Erlanger, Ken-
tucky and, in part, by Nutrition 21, San Diego, California and the American
Physicians Fellowships for Israel.
Manuscript received July 27, 1998; revised manuscript received August 16, 1999,
accepted October 18, 1999.
Journal of the American College of Cardiology Vol. 35, No. 2, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00545-8
Despite the evidence for the link between elevated blood
glucose and altered platelet function, little is known about
the role of blood glucose and plasma insulin levels in
platelet-mediated thrombogenesis. Thus, the aim of this
study was to explore the relationship between platelet-
dependent thrombosis (PDT) and blood glucose. We used
an ex vivo model to examine platelet-thrombus formation in
stable CAD patients. We hypothesized that blood glucose
was positively and independently correlated with PDT and
that this association was likely to be evident even at levels
considered within the normal “nondiabetic” range.
METHODS
Study design and population. Patients were recruited
from a supervised cardiac exercise program at Cedars-Sinai
Medical Center for a randomized trial of oral magnesium
treatment. None of the patients had received treatment with
magnesium at the time of collection of these data. Study
inclusion criteria included men and women age .20 years,
with CAD documented by prior myocardial infarction,
coronary artery bypass surgery operation or coronary an-
giography or angioplasty. Exclusion criteria included unsta-
ble angina, contraindication to exercise testing, congestive
heart failure . New York Heart Association (NYHA) class
IV, chronic diarrhea, renal failure (serum creatinine .
265 mmol/l), acute myocardial infarction ,3 months,
hyper/hypothyroidism, type I diabetes mellitus, clinically-
evident peripheral vascular disease, history of drug or
alcohol abuse, chronic liver disease or refusal to sign the
informed consent. The institutional review board approved
the study, and all participants gave written informed con-
sent.
After an overnight fast, the patients underwent a physical
examination, blood tests for measurement of PDT, platelet
aggregation, flow-cytometry, blood glucose, insulin, lipids,
blood cell count, electrolytes, apolipoprotein A-I, apoli-
poprotein B and fibrinogen, as part of their baseline assess-
ment prior to entry into the randomized trial.
Ex vivo assay for platelet-dependent thrombosis. A 19-
gauge butterfly catheter was inserted atraumatically without
a tourniquet into an antecubital vein. Flowing unanticoagu-
lated venous blood from the patient was drawn over a
segment of prepared porcine aortic media held in a tubular
superfusion flow chamber, by a peristaltic pump placed
distal to the chamber. The chamber was designed to mimic
the cylindrical shape of blood vessels and contained a
window that permitted direct exposure of the aortic media
to the flowing venous blood (17,18). A perfusion chamber
with an internal diameter of 1.0 mm was selected to
generate shear rates of 800 s21, at a flow rate of 5 ml/min for
5 min. This shear rate corresponds to that encountered in
mild to moderately stenosed arteries. The aortic media used
in the superfusion chamber was obtained from normal pigs
by opening the aorta longitudinally and peeling off and
discarding the intima and a thin portion of the subjacent
media. The remaining aortic media was then divided into
35 3 15 mm segments to be placed inside the superfusion
flow chamber to be exposed to flowing blood in the
chamber. Exposure of the arterial media simulates a deep
arterial wall injury with a thrombogenic response similar to
that encountered during plaque rupture.
After the perfusion, the aortic media strips were removed
from the chambers, fixed in 2% gluteraldehyde in 2 M
sodium cacodylate and processed for morphological analysis.
The tissues were stained with hematoxylin-phloxine-
safranin. The stained histological tissue was then analyzed
under a light microscope, and platelet thrombus formation
on the aortic media was quantified morphometrically by
computer-assisted morphometry, using image analysis soft-
ware (Bioscan, Optimas, Washington). All measurements
were made by two different observers who were blinded to
the patients’ blood glucose, and intraassay variability was
5.5 6 5.6%. Thrombus size measurements were expressed
as the average of six analyzed sections per tissue (two in the
proximal, two in the middle and two in the distal section)
expressed as the surface area in square micrometers and
normalized to the cross-sectional diameter of the exposed
media (in millimeters). This morphometric method has
been previously validated and shows a strong correlation
(r 5 0.84, p 5 0.0001) between the amount of indium-
labeled platelets deposited on the media and the morpho-
metrically assessed thrombus size (19).
Platelet aggregation and P-selectin flow cytometry. Ci-
trated whole blood samples (4.5 ml) were collected from the
patients before starting the ex vivo thrombosis experiment,
and these were diluted with an equal volume of isotonic
saline. Collagen (2 mg/ml)-induced whole blood platelet
aggregation was measured by impedance aggregometry (20).
Platelet aggregation was measured as the maximal change in
impedance produced 6 min after the addition of collagen
and expressed in ohms and the rate (slope) expressed in
ohms/min.
Platelet alpha-granule release, detected by expression of
P-selectin (the CD 62P antigen), was measured by whole
blood flow cytometry. Blood samples were prepared for
flow-cytometric analysis using the whole blood method
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described by Janes et al. (21). Five microliters of citrated
blood was added to tubes containing 50 ml of Hepes-
buffered saline (NaCl 0.145 mol/l; KCl 5 mmol/l; MgSO4
1 mmol/l; Hepes 10 mmol/l; pH 7.4) plus 5 ml of fluoros-
cein isothiocyanate- and phycoerythrin-conjugated antihu-
man monoclonal antibodies (Becton Dickinson, Immuno-
cytometry Systems, San Jose, California). After gentle
mixing, the samples were incubated for 20 minutes then
diluted with 0.5 ml of 0.2% formyl saline to inhibit further
activation. A sample incubated with FITC-conjugated ir-
relevant mouse IgG1 at identical concentration served as
negative isotype control. Incubations were carried out at
room temperature (22°C to 26°C). All samples were ana-
lyzed within 1 h of collection in a FACScan flow cytometer
(Becton Dickinson Immunocytometry Systems, San Jose,
California) with LYSIS II software. The platelet population
was identified based on their forward- (size) and side-
(granularity) scatter characteristics and the expression of
GPIIIa (FITC-CD61 profile), a membrane protein present
exclusively on all resting and activated platelets. Activated
platelets were identified based on the expression of
P-selectin (PE-CD62 profile), a platelet alpha-granule pro-
tein which is only expressed on the platelet surface following
activation and degranulation. Platelet CD62P expression
was measured at baseline and following stimulation with
adenosine diphosphate (ADP) (5 mmol/l) (Chronolog
Corp., Havertown, Pennsylvania). For each sample, 5,000
platelets were gated and platelet activation expressed as the
number of CD-62 1 ve platelets as a percentage of
CD-61 1 ve platelets after adjusting for nonspecific fluo-
rescence.
Fasting blood glucose, insulin, blood cell count and
electrolytes. Overnight fasting blood samples were taken
for hemoglobin, total cholesterol, low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol
(HDL-C), very low-density lipoprotein cholesterol, triglyc-
erides, apolipoprotein A-I, apolipoprotein B and fibrinogen
using standard autoanalyzer techniques. Platelet count was
measured from the whole blood by autonalyzer, using
GENS coulter counter. Fasting plasma glucose was mea-
sured with a hexokinase reagent kit (A-gent glucose test,
Abbott, South Pasadena, California). Glucose assays were
run in duplicate, and the intraassay coefficient of variation
ranged from 2% to 3%, depending on the assayed glucose
level. Fasting insulin was measured in plasma as total
immunoreactive insulin (Coat-A-Cout Insulin, Diagnostic
Products Corp., Los Angeles, California) and calibrated to
serum levels for reporting purposes (normal level
,126 pmol/l). Cross-reactivity of this assay with proinsulin
at midcurve is approximately 40%, the intraassay and
interassay coefficients of variation ranged from 5.0% to
10.0% for insulin concentrations reported here and the
lower limit of sensitivity was 8 pmol/l.
Intracellular magnesium levels. Mononuclear cells were
isolated from the whole blood by modified Elin’s method
(22). The intracellular levels of magnesium in isolated
mononuclear cells were measured by atomic absorption
spectrophotometry (normal value: 1.23 6 0.02 mg/mg
protein) (23). Intraassay variability for intracellular magne-
sium was 5.1 6 7.2%, interassay variability was 7 6 5%.
Statistical analysis. Group data are expressed as mean 6
SD. Comparison of biochemical measurements was per-
formed using the unpaired Student t test and Wilcoxon
signed-rank test. The relationship between baseline charac-
teristics and blood glucose concentration with PDT was
performed using the Spearman’s Rank correlation, as ap-
propriate. Log transformations were used to normalize data
for regression analysis. Predictors of PDT were first deter-
mined using univariate linear regression and only statisti-
cally significant univariate predictors of PDT were entered
into multiple stepwise regression analysis. A p value ,0.05
was required to reject the null hypothesis.
RESULTS
Our study population was comprised of 42 stable coronary
patients (37 men and 5 women), with a mean age of 68 6
9 years (range 48–83) and mean body mass index (BMI) of
25 6 4 kg/m2 (range 20–37). All patients had stable CAD
(Table 1) documented by absence of rest pain, crescendo or
new onset angina or unstable angina. Coronary artery
disease was evidenced by a previous myocardial infarction
Table 1. Baseline Characteristics of Study Population (n 5 42)
CAD Risk Factors n (%)
Concomitant
Medication n (%)
Diabetes mellitus 2 (5) Beta-blocking agents 15 (36)
Hypertension 21 (50) Calcium antagonists 14 (36)
Current smokers 0 Hypoglycemic agents 2 (5)
Hypercholesterolemia 27 (64) Lasix 5 (12)
Digoxin 4 (26)
Aspirin 42 (100)
Long-acting nitrates 4 (26)
ACE inhibitors 12 (29)
Lipid lowering agents 27 (64)
ACE 5 angiotensin converting enzyme; CAD 5 coronary artery disease.
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(n 5 23), coronary artery bypass surgery (n 5 26) or
coronary angioplasty (n 5 23) (25 patients had multiple
diagnoses). Among the patients, 2/42 (5%) were diabetic on
oral agents (glyburide and metformin hydrochloride), 8/42
(19%) had blood glucose above the “normal” range
(.6.1 mmol/l) and 16/42 (38%) had elevated insulin levels
(.126 pmol/l). Overall, 7/42 (17%) demonstrated the
dysmetabolic triad of hypertension, obesity (BMI . 27
kg/m2) and insulin levels .126 pmol/l.
Correlation analysis demonstrated that blood glucose was
significantly and positively correlated with PDT (Fig. 1).
This correlation remained significant following exclusion of
the two diabetic patients (r 5 0.41, p 5 0.01). Platelet-
dependent thrombosis also correlated inversely with intra-
cellular magnesium (r 5 20.46, p 5 0.003) and positively
with total cholesterol (r 5 0.34, p 5 0.04). Insulin was
positively correlated with blood glucose (r 5 0.56, p ,
0.001) but not with PDT (r 5 0.19, p 5 0.26). Neither
platelet aggregation nor CD 62P expression correlated with
either blood glucose or PDT (data not shown).
A univariate linear regression analysis assessed the effects
of various covariates on PDT. The variables tested included
glucose, insulin, apolipoprotein B, LDL-C, total choles-
terol, triglycerides, HDL-C, platelet count, platelet aggre-
gation, P-selectin expression (with and without ADP stim-
ulation) and intracellular magnesium levels. Only blood
glucose, intracellular magnesium levels, apolipoprotein B,
LDL-C and total cholesterol were statistically significant
predictors of PDT. Following adjustment in a multivariate
stepwise regression model, blood glucose was the best
predictor of PDT (R2 5 0.19, p , 0.008), followed by
apolipoprotein B (R2 5 0.18, p 5 0.002) and intracellular
magnesium levels (R2 5 0.12, p 5 0.02). Following
exclusion of the two diabetic patients, blood glucose re-
mained a significant predictor of PDT in a stepwise regres-
sion model (R2 5 0.09, p 5 0.03).
When stratified according to those equal or below versus
above the median blood glucose level of 4.9 mmol/l, the two
groups were similar with respect to male gender, age, BMI,
use of medications and the presence of risk factors for CAD.
The two groups were also similar with regard to the baseline
lipid values as well as fibrinogen and platelet count (Table 2)
although apolipoprotein B and insulin were significantly
higher in the group with higher fasting glucose levels.
Platelet-dependent thrombosis was significantly greater in
patients with blood glucose . compared with #4.9 mmol/l
(159 6 141 vs. 67 6 69 mm2/mm, p , 0.01, respectively)
(Fig. 2 and 3). Only 3/42 (7%) of patients with blood
glucose #4.9 mmol/l had PDT above the mean value of
111 6 118 mm2/mm. Neither platelet aggregation, nor
platelet CD62P expression, was significantly different be-
tween the two groups (Fig. 2). Assessment of the platelet
parameters according to fasting blood glucose $6.1 mmol/l
(n 5 8) also demonstrated no significant differences.
The data were further analyzed by arranging the blood
glucose values in quartiles and determining their relation-
ship with PDT values that were normalized by log-
transformation. The results in Table 3 show a continuous
and graded relationship between the two variables that was
nearly statistically significant (F value of 2.66, p 5 0.06,
analysis of variance [ANOVA]). Subjects in the lowest
blood glucose quartile demonstrated the least amount of
PDT. Conversely, subjects in the highest blood glucose
quartile had the highest PDT.
To examine a potential interaction between blood glucose
and insulin levels in modifying PDT, we performed a
two-way ANOVA, where patients were divided into four
groups according to the median fasting blood glucose
(FBG) value of 4.9 mmol/l and normal plasma insulin value
Figure 1. Correlation of fasting blood glucose and platelet-
dependent thrombosis demonstrating a linear correlation (n 5 42).
The correlation was unchanged when the two outlier points
(glucose 5 9.9 and 12.2 mmol/l) or the two diabetic patients were
excluded. FBG 5 fasting blood glucose; PDT 5 platelet-
dependent thrombosis.
Table 2. Laboratory Variables Stratified by Fasting
Blood Glucose
Variable
Fasting Blood Glucose
(mmol/l)
p Value
<4.9
(n 5 21)
>4.9
(n 5 21)
T-Cholesterol (mmol/l) 4.29 6 0.72 4.55 6 0.64 0.25
LDL-C (mmol/l) 2.50 6 0.67 2.79 6 0.64 0.18
HDL-C (mmol/l) 1.10 6 0.20 1.0 6 0.20 0.19
TG (mmol/l) 3.43 6 2.12 4.21 6 3.36 0.23
Apo A-I (mmol/l) 3.36 6 0.49 3.15 6 0.28 0.22
Apo B (mmol/l) 2.22 6 0.72 2.40 6 0.49 , 0.05
Fibrinogen (mmol/l) 7.42 6 0.90 7.88 6 1.99 0.49
PLT count (3103/mL) 198 6 50 195 6 50 0.79
Glucose (mmol/l) 4.4 6 0.3 6.7 6 1.8 , 0.0001
Insulin (pmol/l) 108 6 66 168 6 66 0.01
Values are expressed as mean 6 SD.
Apo 5 apolipoprotein; HDL-C 5 high-density lipoprotein cholesterol; LDL-
C 5 low-density lipoprotein cholesterol; PLT 5 platelets; T-Cholesterol 5 total
cholesterol; TG 5 triglycerides.
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of 126 pmol/l. A significant interaction between insulin and
blood glucose (F 5 8.5, p , 0.006) was demonstrated. The
PDT values were the highest in the group with FBG .
4.9 mmol/l plus insulin levels .126 pmol/l (Fig. 4).
Additional analyses provide support in favor of this inter-
action. Comparison of regression lines (between PDT and
FBG) revealed a significant relationship only in patients
with insulin levels above normal (r2 5 0.33, p 5 0.005) but
not in patients with insulin levels below normal where the
line was virtually flat (Fig. 5A). The ratio of plasma insulin
to FBG was found to have the strongest correlation with
PDT (r2 5 0.77, p , 0.0001) among all variables tested
(Fig. 5B). Thus, these data indicate a significant interaction
between insulin and blood glucose in modulating PDT.
DISCUSSION
Our study is the first to explore the relationship of blood
glucose in PDT in an ex vivo model of thrombogenesis and
test this relationship across a range of blood glucose values,
including a normal “nondiabetic” range. The three principal
findings of this study are:
1) FBG is an independent predictor of PDT in stable CAD
patients,
2) the relationship between blood glucose and PDT is
continuous and graded and evident even in the range of
blood glucose levels considered normal, and
3) plasma insulin levels do not independently predict PDT
but may interact with blood glucose in modulating PDT.
Angiographic and necropsy studies show that patients
with diabetes, especially type II diabetes mellitus, have more
extensive and severe CAD than those without diabetes
(7–9). Plaque rupture with intracoronary thrombosis is
increased, as are subsequent cardiac events. Evidence for
increased platelet adhesion and aggregation (10 –12),
platelet-dependent thrombin generation (13,14) as well as
Figure 2. Bar graphs showing (A) platelet-dependent thrombosis,
(B) P-selectin (CD62 antigen) expression and (C) platelet aggre-
gation in patients with fasting blood glucose # (open bar) and .
(closed bar) 4.9 mmol/l. Data are expressed as mean 6 SD.
Figure 3. Representative histological sections (hematoxylin-
phloxine-safranin stain) showing the platelet-dependent thrombo-
sis deposited (T) on porcine aortic media (M) taken from two
patients: (A) a patient with blood glucose of 6.1 mmol/l, with a
large thrombus area, and (B) a patient with blood glucose of
4.4 mmol/l and a smaller thrombus area.
Table 3. Relationship Between Blood Glucose and PDT
Arranged in Quartiles
Quartile
Blood Glucose
(mmol/l) Log PDT
1st (n 5 10) , 4.4 1.75 6 0.32
2nd (n 5 8) 4.4–4.8 1.83 6 0.25
3rd (n 5 11) 4.9–5.8 1.91 6 0.33
4th (n 5 10) 5.9–11.7 2.14 6 0.31
Analysis of variance, F 5 2.66, p 5 0.06. PDT 5 platelet-dependent thrombosis.
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impaired platelet-mediated vasodilation (15) has been dem-
onstrated in diabetics. Platelet-dependent thrombin gener-
ation and coagulation factors including von Willebrand
factor, factor VII, factor VIII and fibrinogen are signifi-
cantly enhanced in diabetes mellitus (24). Furthermore,
plasma concentrations of plasminogen activator inhibitor 1
are increased in hyperinsulinemia, insulin-resistant states
and type II diabetes mellitus and may account for the
decrease in fibrinolysis (25). Alteration of platelet and
coagulation function appears to correlate with elevated
blood glucose concentration in these patients (16).
Although elevated blood glucose, the hallmark of diabe-
tes, has been incriminated in the adverse cardiovascular
events, recent evidence is emerging that suggests that the
association between elevated blood glucose and coronary
heart disease (CHD) risk may not be confined to the
discrete categories of impaired glucose tolerance or type II
diabetes mellitus. In the Framingham Offspring Study (26),
blood glucose was correlated with the risk of CHD in 2,853
patients not previously diagnosed with diabetes. In addition,
fasting blood glucose was found to be an independent
predictor for cardiovascular mortality in 2,014 healthy men
40–49 years of age (5). Our results are also consistent with
these observations and suggest that risk associated with
blood glucose and CHD risk may be continuous and
graded. As suggested by the interaction data, this relation-
ship is evident even at levels considered within the normal
range, especially if associated with elevated plasma insulin
levels.
Previous work has also demonstrated that platelets from
diabetic patients exhibit an enhanced adhesiveness and
hyperaggregability in response to both strong (thromboxane
A2, collagen, epinephrine) and weak (adenosine diphos-
phate) agonists (10,11). Platelet hyperaggregability has also
been shown to correlate with increased cardiovascular events
in diabetic patients (16). Platelet hyperaggregability has
been observed in newly diagnosed as well as chronic
diabetics, suggesting that the altered platelet function may
be a consequence of metabolic changes rather than the
diabetes per se (10,12). In this study, platelet aggregation
was not significantly different when patients were stratified
by above and below the median glucose of 4.9 mmol/l, a
threshold glucose of $6.1 mmol/l or grouped according to
the presence of diabetes. Several factors may have contrib-
uted to these conflicting results. First, all of the current
study patients were on aspirin therapy, which is known to
suppress platelet aggregation but not platelet adhesion (27).
Second, our PDT studies were performed ex vivo with
unanticoagulated blood, while the previously cited aggrega-
tion studies (10–12,16) were performed in vitro using
citrated blood. Thus, the enhanced platelet adhesion effects
of elevated glucose may have been detectable by our ex vivo
Figure 4. Plot showing interaction between FBG and plasma
insulin in modifying platelet-dependent thrombosis. Patients were
divided into four groups:
1) FBG #4.9 mmol/l plus insulin levels of #126 pmol/l (n 5 12);
2) FBG #4.9 mmol/l plus insulin levels of .126 pmol/l (n 5 9);
3) FBG .4.9 mmol/l plus insulin levels of #126 pmol/l (n 5 8);
and
4) FBG .4.9 mmol/l plus insulin levels of .126 pmol/l (n 5 13).
Data are expressed as mean 6 SD (one-sided error bars). FBG 5
fasting blood glucose; PDT 5 platelet-dependent thrombosis.
Figure 5. (A) Comparison of regression lines in patients with
plasma insulin levels below or above normal (126 pmol/l). (B)
Correlation between the ratio of plasma insulin and FBG and
PDT. FBG 5 fasting blood glucose; PDT 5 platelet-dependent
thrombosis.
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PDT formation measurement, whereas no effect was detect-
able using in vitro platelet aggregation and alpha-granule
release reaction (P-selectin expression) measurements.
Measuring P-selectin expression in response to ADP is
an indicator of platelet reactivity and does not provide direct
information on the circulating activated state of platelets.
However, our data on the surface expression of P-selectin
without the addition of agonists did not show any direct
relationship of glucose levels with platelet degranulation.
Elevated insulin levels may be an independent risk factor
for CAD (6). The validity of this relationship and possible
explanatory mechanism(s), however, remain speculative. In
our current study, insulin levels did not predict PDT
independent of glucose levels. In patients with elevated
insulin levels (.126 pmol/l), PDT was increased only if
blood glucose levels were also increased, suggesting that the
increased thrombogenicity demonstrated in this ex vivo
model may be related to an interaction between insulin and
blood glucose, especially at relatively higher levels.
Apolipoprotein B, the major carrier of LDL-C, was a
significant and positive predictor of PDT in the regression
analysis. Our demonstration of an independent predictive
value for apolipoprotein B in the multivariate analysis argues
against this relationship being simply a marker for insulin
resistance. Indeed, the constellation of dyslipidemia, hyper-
tension and insulin resistance first described by Reaven et al.
(28) has more recently been found to be related to a single
gene locus at or near the lipoprotein lipase on the short arm
of chromosome 8 (29). These findings, combined with our
current study results, suggest that this genetic constellation
of dyslipidemia, hypertension and insulin resistance may
also include prothrombosis.
Study limitations. We studied in a cross-sectional design a
relatively small number of patients with stable CAD receiv-
ing aspirin and lipid lowering therapy and participating in a
supervised cardiac exercise program. It is possible that this
relatively low risk CAD population may have minimized the
observed effects related to blood glucose and PDT. The
mean baseline LDL-C of 2.68 mmol/l in our patients is
close to the ideal goal of the National Cholesterol Educa-
tion Program guidelines for patients with established CAD
of ,2.58 mmol/l (30). Because cholesterol lowering therapy
has been shown to rapidly reduce PDT (31), it is possible
that the near-optimal lipid levels observed in our patients
(the majority of whom were on lipid lowering therapy) may
have minimized the platelet-thrombus burden, thereby
reducing our ability to detect an even more pronounced
effect of blood glucose.
An additional limitation is the ex vivo model used in our
study in which predominantly shear-dependent acute
(5 min) platelet-dependent thrombus formation was exam-
ined. Other factors that modulate thrombogenesis in in vivo
conditions such as coagulation factors and pro- and antifi-
brinolytic factors do not play a critical role in this model.
Nonetheless, this validated model allows us to study platelet
vessel wall interactions under controlled and well-defined
conditions. Although the clinical relevance of thrombus
formation in this experimental model has not been clearly
defined, the reproducibility and simplicity of this ex vivo
system makes it a sensitive tool for study of the interaction
of blood elements with thrombogenic surfaces and assess-
ment of antithrombotic therapeutic interventions.
Conclusions. In summary, elevated FBG is associated with
greater PDT in patients with CAD. This finding appears to
be independent of the presence of diabetes or elevated
insulin levels and is evident in previously considered “nor-
mal” fasting blood glucose levels. These findings suggest
that the increased CAD risk with hyperglycemia may be, in
part, related to enhanced thrombogenesis.
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